ORLANDO, Fla.--(BUSINESS WIRE)--Bioenvision, Inc. (NasdaqGM:BIVN) announced the latest results from clinical studies of clofarabine (Evoltra®) were presented in seven posters today at the 48th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida. The posters featured data on the efficacy and safety of clofarabine in Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Of the data presented, Bioenvision's data included:
